



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy, Pure Communications
(949) 608-0841

XDx's AlloMap® Recommended for Non-Invasive Monitoring of Acute Cellular Rejection in New ISHLT Guidelines for the Care of Heart Transplant Recipients

Guidelines Mark First Formal International Practice Recommendations in Forty Years

BRISBANE, CA, August 12, 2010 – XDx, Inc., a molecular diagnostics company focused on non-invasive gene expression tests for the monitoring of immune-mediated conditions, today announced the inclusion of the AlloMap® test in the inaugural published “International Society of Heart and Lung Transplant Guidelines for the Care of Heart Transplant Recipients.” The Executive Summary of the guidelines is published in the August 2010 issue of *The Journal of Heart and Lung Transplantation* (www.jhltonline.org).

“We congratulate the Society on their painstaking efforts over the last several years, which have culminated in these guidelines,” stated Pierre Cassigneul, president and chief executive officer of XDx. “We believe these comprehensive recommendations, which were developed by 40 experts from nine countries, will set the worldwide standard for the care of heart transplant patients. We are proud to have the use of the AlloMap test described in the recommendations for the non-invasive monitoring of acute heart transplant rejection in these unprecedented evidence based practice guidelines.”

According to the International Society for Heart and Lung Transplantation (ISHLT), medical care of heart transplant recipients has varied significantly from center to center and been guided by the experience of individual clinicians since heart transplantation began in the 1960s. The ISHLT convened experts in all areas of heart transplantation to develop practice guidelines for the care of heart transplant recipients. According to the ISHLT guidelines, Gene Expression Profiling (AlloMap) can be used to rule out the presence of acute cellular rejection (ACR) of grade 2R or greater in appropriate low-risk patients, between six months and five years after heart transplantation.

About AlloMap® Molecular Expression Technology

AlloMap Molecular Expression Testing is a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with a standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008.

About XDx

XDx, based in Brisbane, Calif., is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's non-invasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit www.xdx.com.

#